Press Releases

SAMS Statement on the Establishment of the Select Committee on the Strategic Competition Between the U.S. and the CCP

WASHINGTON, D.C., January 12, 2023 – The Securing America’s Medicines and Supply (SAMS) Coalition today expressed its support for the establishment of the Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party (CCP).

SAMS recognizes the critical importance of the Select Committee and the need for a thorough and nuanced understanding of the challenges associated with CCP competition, particularly with regards to the medical supply chain. The establishment of this select committee will allow for a more informed and strategic approach and will ultimately serve to strengthen the national security of the United States.

“We need to boost production of novel therapies, essential medicines, and medical products in the United States and across a network of allied countries,” said David Sanders, Executive Director of SAMS. “For instance, China controls most of the fermentation-based active pharmaceutical ingredient (API) production in the world.[i] This is just one of many examples of outsized influence by China on our medical supply chain. We can no longer ask patients to rely on overseas manufacturing to this degree.”

SAMS offers its support to the Select Committee and stands ready to contribute our expertise and resources to its work.

About Securing America’s Medicines and Supply

Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive the implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.

[i] Essential Medicines Supply Chain and Manufacturing Resilience Assessment. AdvancedRegenerative Manufacturing Institute (AMRI) and BioFabUSA (p.17).